Delivering wasp venom for cancer therapy

Area of Science:

• Biotechnology
• Drug Delivery
• Oncology

Background:

• Cytolytic peptides show therapeutic promise but face limitations like non-specific activity and rapid degradation.
• Developing targeted delivery systems is crucial to overcome these limitations for effective cancer treatment.

Purpose of the Study:

• To design and evaluate a pro-cytotoxic system for targeted delivery of cytotoxic peptides.
• To enhance the therapeutic efficacy and safety profile of cytotoxic peptides in cancer therapy.

Main Methods:

• Conjugation of cytotoxic peptides (Mitoparan) to poly(L-glutamic acid) (PGA) via protease-cleavable linkers.
• Incorporation of a HER2-targeting peptide for selective tumor cell binding.
• In vitro and in vivo evaluation of the pro-cytotoxic system's activity and targeting specificity.

Main Results:

• The conjugated cytotoxic peptide (Mitoparan) was inactive until released by tumor-specific proteases (MMP-2, cathepsin B).
• The HER2-targeting moiety enhanced selective peptide release within HER2-positive tumor cells.
• The pro-cytotoxic system demonstrated improved stability and controlled release kinetics.

Conclusions:

• The developed pro-cytotoxic system effectively targets tumor cells and releases active cytotoxic peptides in a controlled manner.
• This approach holds potential for improving the maximum tolerated dose and pharmacokinetic parameters of cytotoxic peptides.
• The system offers a promising strategy for enhancing the efficacy and safety of peptide-based cancer therapeutics.